Triumeq (Abacavir/Dolutegravir/Lamivudine) for HIV

Overview
Triumeq is a prescription drug approved by the Food and Drug Administration (FDA) to treat HIV-1 infection. Triumeq is a combination drug composed of Abacavir, Dolutegravir, and Lamivudine, which are also known respectively by the abbreviations ABC, DTG, and 3TC. Abacavir and Lamivudine are both antiviral medications of the nucleoside reverse transcriptase inhibitor (NRTI) class. Dolutegravir is an antiviral medication of the integrase strand transfer inhibitor (INSTI) class. All three drugs are believed to work by preventing HIV from replicating in cells.

How do I take it?
Prescribing information states that Triumeq is taken once daily. Triumeq comes in tablet form.

Side effects
The FDA-approved label for Triumeq lists common side effects including headache, fatigue, and insomnia. Rare but serious side effects listed for Triumeq include severe hypersensitivity reactions, lactic acidosis (a metabolic disorder), hepatomegaly (enlarged liver) with steatosis (fatty degeneration), and severe exacerbation of Hepatitis B.

For more details about this treatment, visit:

Triumeq highlights of prescribing information – Viiv Healthcare

Overview of HIV Treatments – AIDS.gov